Angela Hague
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Angela Hague has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Christos Paraskeva
CRC Colorectal Tumour Biology Research Group, Department of Pathology and Microbiology, University of Bristol, School of Medical Sciences, Bristol, United Kingdom
8 shared publications A M Manning
2 shared publicationsD J Elder
Department of Pathology and Microbiology, School of Medical Sciences, University of Bristol, University Walk, Bristol, BS8 1TD, United Kingdom
2 shared publications- Helen Louise Robbins
University of Birmingham 1 Department of Immunology and Immunotherapy Birmingham, United Kingdom
2 shared publications J W Van Der Stappen
2 shared publicationsSuzanne Huntley
Department of Oral and Dental Science, University of Bristol Dental School, Lower Maudlin Street, Bristol, BS1 2LY, UK
2 shared publications
Latest Publications
- 8 July 2022
- Published by Elsevier in Oral Oncology
- Vol. 132, 105979
Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge
- 8 July 2022
- Published by Elsevier in Oral Oncology
- Vol. 132, 105979
Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge
- 16 November 2016
- Published by Taylor & Francis in International Journal of Endocrine Oncology
- Vol. 3 (4) , 281-284
Akt as a Potential Prognostic Marker in Neuroendocrine Tumors: A Possibility?
- 16 November 2016
- Published by Taylor & Francis in International Journal of Endocrine Oncology
- Vol. 3 (4) , 281-284
Akt as a Potential Prognostic Marker in Neuroendocrine Tumors: A Possibility?
- Open Access
- 11 January 2016
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 6, 188
The PI3K/Akt Pathway in Tumors of Endocrine Tissues
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a key driver in carcinogenesis. Defects in this pathway in human cancer syndromes such as Cowden’s disease and Multiple Endocrine Neoplasia result in tumors of endocrine tissues, highlighting its importance in these cancer types. This review explores the growing evidence from multiple animal and in vitro models and from analysis of human tumors for the involvement of this pathway in the following: thyroid carcinoma subtypes, parathyroid carcinoma, pituitary tumors, adrenocortical carcinoma, phaeochromocytoma, neuroblastoma, and gastroenteropancreatic neuroendocrine tumors. Whilst data are not always consistent, immunohistochemistry performed on human tumor tissue has been used alongside other techniques to demonstrate Akt overactivation. We review active Akt as a potential prognostic marker and the PI3K pathway as a therapeutic target in endocrine neoplasia.
- 11 January 2016
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 6, 188
Open AccessThe PI3K/Akt Pathway in Tumors of Endocrine Tissues
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a key driver in carcinogenesis. Defects in this pathway in human cancer syndromes such as Cowden’s disease and Multiple Endocrine Neoplasia result in tumors of endocrine tissues, highlighting its importance in these cancer types. This review explores the growing evidence from multiple animal and in vitro models and from analysis of human tumors for the involvement of this pathway in the following: thyroid carcinoma subtypes, parathyroid carcinoma, pituitary tumors, adrenocortical carcinoma, phaeochromocytoma, neuroblastoma, and gastroenteropancreatic neuroendocrine tumors. Whilst data are not always consistent, immunohistochemistry performed on human tumor tissue has been used alongside other techniques to demonstrate Akt overactivation. We review active Akt as a potential prognostic marker and the PI3K pathway as a therapeutic target in endocrine neoplasia.
- 26 August 2011
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 18 (12) , 1944-1947
International EMBO Molecular Medicine Workshop 2011 on ‘Cell Death and Disease’
- 26 August 2011
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 18 (12) , 1944-1947
International EMBO Molecular Medicine Workshop 2011 on ‘Cell Death and Disease’
- Open Access
- 26 April 2011
- Published by Springer Nature in British Journal of Cancer
- Vol. 104 (9) , 1459-1471
Co-overexpression of Bag-1 and heat shock protein 70 in human epidermal squamous cell carcinoma: Bag-1-mediated resistance to 5-fluorouracil-induced apoptosis
The aim was to determine whether Bcl-2-associated athanogene-1 (Bag-1) and/or its binding protein heat shock protein-70 (Hsp70) exhibit deregulated expression in epidermal squamous cell carcinoma (SCC) and whether Bag-1 confers apoptosis resistance. Immunohistochemistry for Bag-1 and Hsp70 was performed on 60 epidermal SCC and 10 normal skin samples. The epidermal SCC cell line SCC-13 was treated with 5-fluorouracil (5-FU) after Bag-1 knockdown to determine whether high Bag-1 levels contribute to growth and/or apoptosis resistance. Normal epithelium expressed primarily nuclear Bag-1. Most tumours showed reduced nuclear Bag-1 staining, but a subset exhibited strong Bag-1 staining, with cytoplasmic Bag-1 staining intensity correlating with cytoplasmic Hsp70 staining intensity (rs=0.462; PP<0.001). Bag-1 knockdown resulted in markedly reduced SCC-13 cell yield, increased spontaneous apoptosis and enhanced sensitivity to 5-FU-induced apoptosis. Apoptosis induced by 5-FU in the Bag-1-knockdown cells was significantly greater than the additive apoptotic effect of 5-FU or Bag-1 knockdown alone. Overexpression of Bag-1 and Hsp70 in poorly differentiated SCC may confer both enhanced tumour cell growth and apoptosis resistance. Bag-1 may contribute to the resistance of more advanced epidermal SCC to chemotherapy.
- 26 April 2011
- Published by Springer Nature in British Journal of Cancer
- Vol. 104 (9) , 1459-1471
Open AccessCo-overexpression of Bag-1 and heat shock protein 70 in human epidermal squamous cell carcinoma: Bag-1-mediated resistance to 5-fluorouracil-induced apoptosis
The aim was to determine whether Bcl-2-associated athanogene-1 (Bag-1) and/or its binding protein heat shock protein-70 (Hsp70) exhibit deregulated expression in epidermal squamous cell carcinoma (SCC) and whether Bag-1 confers apoptosis resistance. Immunohistochemistry for Bag-1 and Hsp70 was performed on 60 epidermal SCC and 10 normal skin samples. The epidermal SCC cell line SCC-13 was treated with 5-fluorouracil (5-FU) after Bag-1 knockdown to determine whether high Bag-1 levels contribute to growth and/or apoptosis resistance. Normal epithelium expressed primarily nuclear Bag-1. Most tumours showed reduced nuclear Bag-1 staining, but a subset exhibited strong Bag-1 staining, with cytoplasmic Bag-1 staining intensity correlating with cytoplasmic Hsp70 staining intensity (rs=0.462; PP<0.001). Bag-1 knockdown resulted in markedly reduced SCC-13 cell yield, increased spontaneous apoptosis and enhanced sensitivity to 5-FU-induced apoptosis. Apoptosis induced by 5-FU in the Bag-1-knockdown cells was significantly greater than the additive apoptotic effect of 5-FU or Bag-1 knockdown alone. Overexpression of Bag-1 and Hsp70 in poorly differentiated SCC may confer both enhanced tumour cell growth and apoptosis resistance. Bag-1 may contribute to the resistance of more advanced epidermal SCC to chemotherapy.
- 16 February 2009
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 16 (3) , 512-514
Cell death mechanisms: life in the balance
- 16 February 2009
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 16 (3) , 512-514
Cell death mechanisms: life in the balance
- 11 December 2007
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 24 (5) , 381-389
Cell motility assays
This report summarises practical aspects to measuring cell motility in culture. The methods described here were discussed at a 1-day European Tissue Culture Society (ETCS-UK) workshop organised by John Masters and Gareth E Jones that was held at University College London on 19th April 2007.
- 11 December 2007
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 24 (5) , 381-389
Cell motility assays
This report summarises practical aspects to measuring cell motility in culture. The methods described here were discussed at a 1-day European Tissue Culture Society (ETCS-UK) workshop organised by John Masters and Gareth E Jones that was held at University College London on 19th April 2007.
- 2 February 2007
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 14 (4) , 885-886
Death in the Alps
- 2 February 2007
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 14 (4) , 885-886
Death in the Alps
- 1 January 2007
- Published by Springer Nature
- p. 101-109
Cell motility assays
- 16 September 2004
- Published by Wiley in The Journal of Pathology
- Vol. 204 (2) , 175-182
Caspase‐3 expression is reduced, in the absence of cleavage, in terminally differentiated normal oral epithelium but is increased in oral squamous cell carcinomas and correlates with tumour stage
Oral carcinomas are known to have a greater apoptotic index than normal oral epithelium, evident as shrinking cells with condensed chromatin. In this study, these morphologically apoptotic cells stained positively for cleaved (active) caspase‐3. In normal oral epithelium, cleaved caspase‐3 positive‐cells were only rarely detected. The terminally differentiated surface epithelial layers did not express cleaved caspase‐3. The caspase‐3 pro‐enzyme showed a gradient of expression in normal oral epithelium, decreasing with differentiation. No expression was detectable in surface epithelial layers. Lack of expression of the major ‘executioner’ caspase‐3 may, at least in part, explain differences in morphology between terminally differentiated and apoptotic cells. In cancers of different tissue origins, caspase‐3 pro‐enzyme expression can be either increased or decreased compared with normal tissue counterparts. To determine how caspase‐3 expression alters during oral carcinogenesis, caspase‐3 expression was compared in 39 samples of normal oral epithelium and 54 oral squamous cell carcinomas. Squamous cell carcinomas had more intense caspase‐3 staining than normal epithelium (p < 0.001). Moreover, within the oral squamous cell carcinoma series, there was significantly more intense nuclear and cytoplasmic staining with increasing STNMP stage (p = 0.017 and 0.03, respectively). This was a reflection of significant associations with site (S), palpable lymph nodes (N), and differentiation (P). Both caspase‐3 staining intensity and the percentage of cells positive for caspase‐3 were inversely associated with differentiation. Studies of the mechanisms by which high levels of caspase‐3 expression are tolerated in oral carcinoma cells may identify targets that can be used to harness caspase‐3 overexpression for therapeutic benefit. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 16 September 2004
- Published by Wiley in The Journal of Pathology
- Vol. 204 (2) , 175-182
Caspase‐3 expression is reduced, in the absence of cleavage, in terminally differentiated normal oral epithelium but is increased in oral squamous cell carcinomas and correlates with tumour stage
Oral carcinomas are known to have a greater apoptotic index than normal oral epithelium, evident as shrinking cells with condensed chromatin. In this study, these morphologically apoptotic cells stained positively for cleaved (active) caspase‐3. In normal oral epithelium, cleaved caspase‐3 positive‐cells were only rarely detected. The terminally differentiated surface epithelial layers did not express cleaved caspase‐3. The caspase‐3 pro‐enzyme showed a gradient of expression in normal oral epithelium, decreasing with differentiation. No expression was detectable in surface epithelial layers. Lack of expression of the major ‘executioner’ caspase‐3 may, at least in part, explain differences in morphology between terminally differentiated and apoptotic cells. In cancers of different tissue origins, caspase‐3 pro‐enzyme expression can be either increased or decreased compared with normal tissue counterparts. To determine how caspase‐3 expression alters during oral carcinogenesis, caspase‐3 expression was compared in 39 samples of normal oral epithelium and 54 oral squamous cell carcinomas. Squamous cell carcinomas had more intense caspase‐3 staining than normal epithelium (p < 0.001). Moreover, within the oral squamous cell carcinoma series, there was significantly more intense nuclear and cytoplasmic staining with increasing STNMP stage (p = 0.017 and 0.03, respectively). This was a reflection of significant associations with site (S), palpable lymph nodes (N), and differentiation (P). Both caspase‐3 staining intensity and the percentage of cells positive for caspase‐3 were inversely associated with differentiation. Studies of the mechanisms by which high levels of caspase‐3 expression are tolerated in oral carcinoma cells may identify targets that can be used to harness caspase‐3 overexpression for therapeutic benefit. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.